Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network - Institut de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition Access content directly
Journal Articles Diabetes, Obesity and Metabolism Year : 2022

Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network

H Mosbah
  • Function : Author
E Nobécourt
  • Function : Author
F Archambeaud
  • Function : Author
E Bismuth
  • Function : Author
M Cartigny
  • Function : Author
A Daguenel
  • Function : Author
M Fichet
  • Function : Author
J Gautier
  • Function : Author
S Janmaat
  • Function : Author
I Jéru
  • Function : Author
C Legagneur
  • Function : Author
L Leguier
  • Function : Author
J Maitre
  • Function : Author
E Mongeois
  • Function : Author
C Poitou
  • Function : Author
Y Reznik
  • Function : Author
A Spiteri
  • Function : Author
F Travert
  • Function : Author
B Vergès
  • Function : Author
J Zammouri
  • Function : Author
C Vatier

Abstract

Aims: To describe baseline characteristics and follow-up data in patients with lipodystrophy syndromes treated with metreleptin in a national reference network, in a real-life setting. Patients and Methods: Clinical and metabolic data from patients receiving metreleptin in France were retrospectively collected, at baseline, one year and at the latest follow-up during treatment. Results: Forty-seven patients with lipodystrophy including generalized lipodystrophy (GLD, n=28) and partial lipodystrophy (PLD, n=19) received metreleptin over the last decade. At baseline, age was 29.3 [16.6-47.6] (years, median [interquartile range]); BMI 23.8 kg/m2 [21.2-25.7]; serum leptin 3.2 [1.0- 4.9] ng/mL); 94% of patients had diabetes (66% insulin-treated), 53% hypertension, and 87% dyslipidemia. Metreleptin therapy, administered during 31.7 [14.2-76.0] months, was ongoing in 77% of patients at the latest follow-up. In patients with GLD, HbA1c (%) and fasting triglycerides (mmol/L) significantly decreased from baseline to one year-metreleptin treatment, from 8.4 [6.5-9.9] to 6.8 [5.6- 7.4], and 3.6 [1.7-8.5] to 2.2 [1.1-3.7] respectively (p<0.001), with a sustained efficacy thereafter. In patients with PLD, HbA1c (%) was not significantly modified from 7.7 [7.1-9.1] at baseline vs 7.7 [7.4- 9.5] at one-year), and the decrease in fasting triglycerides (mmol/L), from 3.3 [1.9-9.9] to 2.5 [1.6-5.3], p<0.01) was not confirmed at the latest assessment (5.2 [2.2-11.3]). However, among PLD patients, at one-year, 61 % were responders regarding glucose homeostasis, with lower baseline leptin levels compared to non-responders, and 61% were responders regarding triglyceridemia. Liver enzymes significantly decreased only in the GLD group. Conclusions: In this real-life setting study, metabolic outcomes are improved under metreleptin therapy in patients with GLD. The therapeutic indication of metreleptin needs to be clarified in patients with PLD.
Fichier principal
Vignette du fichier
Diabetes Obesity Metabolism - 2022 - Mosbah - Therapeutic indications and metabolic effects of metreleptin.pdf (716.49 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03649731 , version 1 (22-04-2022)

Identifiers

Cite

H Mosbah, M Vantyghem, E Nobécourt, F Andreelli, F Archambeaud, et al.. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network. Diabetes, Obesity and Metabolism, 2022, ⟨10.1111/dom.14726⟩. ⟨hal-03649731⟩
121 View
34 Download

Altmetric

Share

Gmail Facebook X LinkedIn More